201530-41-8
201530-41-8
Chemical Structure
Deferasirox
Synonym(s): ICL 670
- CAS No.: 201530-41-8
- Formula:C21H15N3O4
- Molecular Weight:373.36
IUPAC Name: 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid
InChIKey: BOFQWVMAQOTZIW-UHFFFAOYSA-N
SMILES: O=C(O)C1=CC=C(N2N=C(C3=CC=CC=C3O)N=C2C4=CC=CC=C4O)C=C1
Biological Activity: Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Deferasirox | 99.86% | Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deferasirox (Standard) | ≥98% | Deferasirox (Standard) is the analytical standard of Deferasirox. This product is intended for research and analytical applications. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deferasirox-d4 | Deferasirox-d4 is the deuterium labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Deferasirox-13C6 | Deferasirox-13C6 (ICL 670-13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30(3):638-45. [Content Brief]
- [2]. Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126(4):241-5. [Content Brief]
- [3]. Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41(6):539-46. [Content Brief]
